Study description/purpose
Dementia, and the cognitive decline that precedes it, are feared and increasingly common disorders in our populations. In Australia, an estimated 250 people are newly diagnosed with dementia each day. Around the world, there is a new case every three seconds around the world, with numbers predicted to rise to 152 million by 2050.
Dementia represents a diagnostic point in a long disease process that begins symptom-free with pathology occurring 20 to 30 years prior to diagnosis. As no medications are currently available to treat dementia, the best option is prevention through early intervention of those at increased risk of the condition.
Over 30 potential modifiable dementia risk factors have been proposed, but recent World Health Organisation guidelines for dementia risk reduction made strong recommendations for blood pressure (BP) lowering.
The study aims to determine the feasibility of an online and telehealth clinical trial of more intensive BP-lowering provided by a ‘Triple Pill’ strategy as an adjunct to standard care, compared to standard care, on the attenuation of cognitive decline in midlife participants who are at a greater than average risk of developing dementia in later life.
What’s Involved?
Randomised participants will receive study medication for 4 weeks, and all visits will be conducted remotely.
